Beike Biotechnology

Multiple Sclerosis: Patient-reported outcomes

Patient-reported outcomes after stem cell therapy for Multiple Sclerosis, based on 0 patients in our follow-up registry.

Detailed outcome data is temporarily unavailable for this condition.

← Back to treatment overview
Internationally accredited

Held to global laboratory and biologics standards.

U.S. Pharmacopeial Convention (USP) Clinical Laboratory Improvement Amendments (CLIA) Center for Devices and Radiological Health (CDRH) Center for Biologics Evaluation and Research (CBER) American Association of Tissue Banks (AATB)